Hospital Universitario Puerta del Mar -ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2024

  1. Why is it necessary to produce a BCG strain in Spain?

    Actas Urologicas Espanolas

2023

  1. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

    Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126

  2. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply

    Actas Urologicas Espanolas

  3. Hormone sensitive protocol for metastatic prostate cancer, an update

    Actas Urologicas Espanolas, Vol. 47, Núm. 4, pp. 244-249

  4. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial

    European urology oncology, Vol. 6, Núm. 1, pp. 58-66

2022

  1. Non-metastatic castration-resistant prostate cancer: management recommendations

    Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 193-213

2019

  1. Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting

    Actas Urologicas Espanolas, Vol. 43, Núm. 7, pp. 364-370

2014

  1. Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options

    Actas Urologicas Espanolas

2013

  1. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

    British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130

  2. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572